Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 3/20 | 0.50 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.50 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.50 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | RXRA | P19793 | 4/20 | 0.46 |
| ▸ | RXRB | P28702 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | RXRG | P48443 | 2/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6260237 | 0.90 | PTGER1 (0.62) | PTGER1PTGER4PTGER3PTGER2HTR1A | |
| SCHEMBL8409744 | 0.83 | HTR1A (0.69) | PTGER1PTGER4PTGER3PTGER2HTR1A | |
| SCHEMBL8162286 | 0.81 | SPHK2 (0.57) | PTGER1PTGER4PTGER3PTGER2HTR1A | |
| SCHEMBL8696840 | 0.81 | HTR1A (0.50) | PTGER1PTGER4PTGER3PTGER2HTR1A | |
| SCHEMBL8174051 | 0.80 | NPC1 (0.53) | PTGER1PTGER4PTGER3PTGER2HPGD | |
| SCHEMBL8169311 | 0.76 | LMNA (0.66) | PTGER1HTR1ADRD2HPGDL3MBTL1 | |
| SCHEMBL6257700 | 0.76 | POLB (0.64) | LMNAGAA | |
| SCHEMBL8698068 | 0.75 | HTR1A (0.53) | PTGER1PTGER4PTGER3PTGER2HTR1A | |
| SCHEMBL8698071 | 0.74 | PTGER1 (0.52) | PTGER1PTGER4PTGER3PTGER2HTR1A | |
| SCHEMBL31757878 | 0.73 | HTR1A (0.57) | PTGER1PTGER4PTGER3PTGER2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0752421-B1 | Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists | ASTRAZENECA AB (SE) | 2005-10-12 | — | — | EP | disclosed |
| US-6787562-B2 | ANALGESICS; OSTEOPOROSIS | ZENECA LTD. (GB) | 2004-09-07 | — | — | US | disclosed |
| US-20030139418-A1 | Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists | SYNGENTA LIMITED (GB) | 2003-07-24 | — | — | US | disclosed |
| US-6057345-A | ANTAGONISTS OF THE PAIN ENHANCING EFFECTS OF E-TYPE PROSTAGLANDINS; USED IN PAIN RELIEF | ZENECA LIMITED (GB) | 2000-05-02 | — | — | US | disclosed |
| EP-0752421-A1 | Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists | ZENECA LIMITED (GB) | 1997-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139418-A1 | Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists | PTGER1, PTGDR, PTGER2 | PTGER1 1/4885PTGER4 4/4885PTGER3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.